Welcome to IJPT

Alice in Wonderland Syndrome, also known as Todd's syndrome or Lilliputian hallucinations, is a rare disorienting
neuropsychological condition that affects perception. The syndrome was originally coined by Dr. John Todd in 1955 and
was named after the sensations experienced by the character Alice in Lewis Carroll’s novel “Alice’s Adventures in
Wonderland”. AIWS can occur at any age but mostly in children less than 18 years old. The symptoms of AIWS include
metamorphopsia, bizarre distortions of their body image, and bizarre perceptual distortions of form, size, movement or
color. Additionally, patients can experience auditory hallucinations and changes in their perception of time. This syndrome
has many different etiologies such as Epstein-Barr virus infection, migraine, temporal lobe epilepsy, brain tumours and
psychostimulant drugs. Auxiliary investigations including blood tests, brain MRI and EEG are strongly advised for the
diagnosis of AIWS. The long-term prognosis typically depends on the root cause of the syndrome, and the underlying
chronic conditions such as migraine and epilepsy must be evaluated and treated. Alice in Wonderland Syndrome has no
proven, effective treatment. Whenever treatment is considered useful and necessary, it needs to be aimed at the suspected
underlying condition. Further research is required to establish an effective treatment regimen.

The emerging resistance of some antimicrobial species to synthetic antimicrobial agents makes it necessary to
continue the search for new antimicrobial agents. As vast number of reports are available pertaining to the antimicrobial
activities of coumarins and pyrazolines, novel coumarino pyrazolin-5-one derivatives were designed. Molecular docking
studies was carried out to identify the specificity of these derivatives using ‘Glide’ on two antibacterial targets;
Dihydrofolate reductase (DHFR) of Staphylococcus aureus (PDB ID: 3SRW); Dihydrofolate reductase of Escherichia Coli
(PDB ID: 1RX7). From the results obtained, it was found that compounds CP1c and CP1e were more potent against DHFR

Most of the nitrogen and oxygen containing heterocycles possess wide range of biological activities. Combination
of heterocylic molecules proved to be a successful approach for augmenting biological activities. Novel hybrid Molecules of
Benzoxazinyl Pyrazole Arylidenes were designed and synthesized by appropriate synthetic routes.Novel hybrid molecules
were screened for their in silico antibacterial activity. This approach paved the way to explore the specificity of newly
synthesized hydrid molecules. The novel hybrid molecules were docked with dihydrofolate reductase of S.aureus (PDB ID:
3SRW); dihydrofolate reductase of E.coli (PDB ID: 1RX7); The docked poses were ranked based on their docking scores
and ligand –receptor binding free energy with the enzyme. The above studies revealed that docking of hybrid molecules (4-
hydroxy.3-methoxybenzylidene substituted benzoxazinyl pyrazole) showed promising inhibitory activity. Thus molecular
docking helped in exploring the selectivity of newly synthesized hybrid molecules in the active site of enzyme. ADME
properties of hybrid molecules were predicted using QuikProp and all the molecules showed drug like properties

Werewolf ‘s syndrome, which is scientifically known as hypertrichosis is an unusual genetic disorder. It is characterised by abnormal uncontrolled hair growth, which can be either generalized (all over the body) or localized (confined to certain parts). WWS is classified mainly as congenital or acquired. Congenital hypertrichosis is a condition, where babies are born with abnormal uncontrolled hair growth. In acquired hypertrichosis, hair growth develops later in life due to lifestyle or some drugs. Some types of congenitalhypertrichosis are hypertrichosislanuginosa, generalized hypertrichosis, terminal hypertrichosis, localized hypertrichosis, nevoid hypertrichosis and circumscribed hypertrichosis. Acquired hypertrichosisis classified as acquired hypertrichosislanuginosa, acquired generalized hypertrichosis, acquired patterned hypertrichosis, and acquired localized hypertrichosis. Common symptoms are abnormal hair growth and teeth defects, enlarged gums (Gingival Hyperplasia),mental retardation etc. Most of the hypertrichosis are caused due to genetic reasons.Acquired werewolf syndrome also can be caused by cancer or as side effects of certain medications (latanoprost, cyclosporine, acetazolamide, streptomycin). Congenital hypertrichosis is rare, as compared to the acquired ones. Few types of werewolf syndrome can only be controlled with treatment; while others are managed with cosmetic hair removal,depilatory creams, and electrolysis. Further research is required to establish an effective treatment regimen to patients with WWS.

Leontiasis ossea, also known as leontiasis, lion face or Lion Face Syndrome, is a rare medical condition used to describe a number of conditions that result in the affected patient's face resembling that of a lion. It is characterized by an overgrowth of the facial and cranial bones. It is most frequently associated with craniofacial fibrous dysplasia, other conditions may mimic leontiasis ossea including Paget's disease, fibrous dysplasia, hyperparathyroidism and renal osteodystrophy. The medical term leontiasis ossea is reported to be first coined in 1864 by the famed Virchow. Lion face syndrome is quite rare and involves extra growth of the bones of the face, particularly the maxilla or upper jaw. Growth in this area narrows the nasal opening, modifies the mouth, and can even press on the eye orbits and optic nerve, compromising vision . Less common form affects all the cranial bones as well as those of the face. Suffering from this form person loses all senses one by one and it leads to death from cerebral pressure. The overgrowth can lead to breathing and eating challenges. It can occur at any age. The symptoms include cluster headache, fibrous dysplasis, nasal obstruction, mutation in the POFUT1 gene and TWIST2 gene. There is no treatment other than exposing the overgrown bone, and chipping away pieces, or excising entirely where possible.

Anticoagulants are the cornerstone therapy for thrombosis prevention and treatment. While anticoagulants are commonly employed, their use is often associated with adverse drug events and increased readmission rates.A prospective observational study was carried out for 6 months with a sample size of 49 patients. 8-Item Morisky Medication Adherence Scale (MMAS-8) was used to assess medication adherence and Anti-coagulation knowledge Assessment (AKA) questionnaire was used to assess the knowledge of the patients. Total study patients were divided into two groups [Control group i.e. without pharmaceutical care (n = 22) and Pharmaceutical care group (n=27)]. International Normalized Ratio (INR) and activated Partial Thromboplastin Time (aPTT) were observed at baseline, first follow-up and second follow-up in the patients. The AKA scores of pharmaceutical care group and control group were analyzed by one way ANOVA followed by Dunnet t test. Results indicated AKA score has not significantly altered at base line, first follow-up and second follow-up. The AKA scores of pharmaceutical care group and control group were analyzed by one way ANOVA followed by Dunnet test. Results indicated that AKA score has significantly (p<0.001 increased in first follow-up and second follow-up in comparison to base line scores.The study showed that INR and aPTT value of the patients can be kept within the recommended range when physicians and pharmacist collaboratively manage patients’ anti-coagulation therapy.Since, clinical pharmacist can effectively manage anticoagulation therapy and provide optimal care to the patients and there is a strong need for physician- pharmacist collaboration in health care setup which will empower patients to improve quality of care and to achieve better therapeutic outcome with improved safety in patients who receives anticoagulation therapy.